Bi-weekly liposomal doxorubicin for advanced breast cancer in elderly women (≥70years)

Journal of Geriatric Oncology

Volumn 4, Issue 4, 2013, Pages 340-345

  Basso, Umberto ^a   Roma, Anna ^a   Brunello, Antonella ^a   Falci, Cristina ^a   Fiduccia, Pasquale ^a   Banzato, Alberto ^a   Bononi, Antonio ^b   Gusella, Milena ^b   Vamvakas, Lampros ^c   Zagonel, Vittorina ^a   Monfardini, Silvio ^a,d  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b Azienda ULSS 18   (Italy)

^c UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^d IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

Author keywords

Anthracyclines; Breast cancer; Chemotherapy; Elderly; Liposomal doxorubicin; Toxicity

Indexed keywords

ANTHRACYCLINE; DOXORUBICIN; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; HORMONE;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BREAST CANCER; BREAST METASTASIS; CANCER GROWTH; CANCER HORMONE THERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; FITNESS; FOLLOW UP; GERIATRIC ASSESSMENT; HAND FOOT SYNDROME; HEART DISEASE; HEMATOLOGIC DISEASE; HUMAN; INFECTION; LUNG EMBOLISM; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OBSERVATIONAL STUDY; PRIORITY JOURNAL; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT REFUSAL; VOMITING; VULNERABLE POPULATION;

ANTHRACYCLINES; BREAST CANCER; CHEMOTHERAPY; ELDERLY; LIPOSOMAL DOXORUBICIN; TOXICITY;

AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84884977834     PISSN: 18794068     EISSN: 18794076     Source Type: Journal    
DOI: 10.1016/j.jgo.2013.07.004     Document Type: Article

References (26)

1. Brunello A., Roma A., Falci C., Basso U. Chemotherapy and targeted agents for elderly women with advanced breast cancer. Recent Pat Anticancer Drug Discov 2008, 3:187-202.
2. Biganzoli L., Wildiers H., Oakman C., Marotti L., Loibl S., Kunkler I., et al. Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol 2012, 13:148-160.
3. Aapro M., Monfardini S., Jirillo, Basso U. Management of primary and advanced breast cancer in older unfit patients (medical treatment). Cancer Treat Rev 2009, 35:503-508.
4. Morris P.G., Fornier M.N. Optimizing the use of anthracyclines in older patients with breast cancer. Crit Rev Oncol Hematol 2001, 77:131-141.
5. Gabizon A., Shmeeda H., Grenader T. Pharmacological basis of pegylated liposomal doxorubicin: impact on cancer therapy. Eur J Pharm Sci 2012, 12:388-398.
6. O'Brien M.E., Wigler N., Inbar M., Rosso R., Grischke E., Santoro A., et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004, 15:440-449.
7. 2 every 4weeks in previously treated patients with metastatic breast cancer. Oncology 2006, 70:141-146.
8. Al-Batran S.E., Bischoff J., von Minckwitz G., Atmaca A., Kleeberg U., Meuthen I., et al. The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial. Br J Cancer 2006, 94:1615-1620.
9. Minisini A.M., Andreetta C., Fasola G., Puglisi F. Pegylated liposomal doxorubicin in elderly patients with metastatic breast cancer. Expert Rev Anticancer Ther 2008, 8:331-342.
10. Biganzoli L., Coleman R., Minisini A., Hamilton A., Aapro M., Therasse P., et al. A joined analysis of two European Organization for the Research and Treatment of Cancer (EORTC) studies to evaluate the role of pegylated liposomal doxorubicin (Caelyx) in the treatment of elderly patients with metastatic breast cancer. Lancet Oncol 2007, 61:84-89.
11. Wedding U., Honecker F., Bokemeyer C., Pientka L., Höffken K. Tolerance to chemotherapy in elderly patients with cancer. Cancer Control 2007, 14:44-56.
12. Basso U., Monfardini S. Multidimensional geriatric evaluation in elderly cancer patients: a practical approach. Eur J Cancer Care (Engl) 2004, 13:424-433.
13. Pallis A.G., Ring A., Fortpied C., Penninckx B., Van Nes M.C., Wedding U., et al. Wildiers H; European Organisation for Research and Treatment of Cancer Elderly Task Force. EORTC workshop on clinical trial methodology in older individuals with a diagnosis of solid tumors. Ann Oncol 2011, 22:1922-1926.
14. Sehouli J., Oskay-Ozcelik G., Kühne J., Stengel D., Hindenburg H.J., Klare P. Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer: results of a multicenter phase-II trial. Ann Oncol 2006, 17:957-961.
15. Brunello A., Loaldi E., Balducci L. Dose adjustment and supportive care before and during treatment. Cancer Treat Rev 2009, 35:493-498.
16. Basso U., Tonti S., Bassi C., Brunello A., Pasetto L.M., Scaglione D., et al. Management and survival of elderly cancer patients (≥70years) treated as inpatients whithin a geriatric oncology program: which benefit for the frail subgroup?. Crit Rev Oncol Hematol 2008, 66:163-170.
17. Basso U., Fratino L., Brunello A., Lumachi F., De Salvo G.L., Lonardi S., et al. Which benefit from adding gemcitabine to vinorelbine in elderly (>or=70years) women with metastatic breast cancer? Early interruption of a phase II study. Ann Oncol 2007, 18:58-63.
18. Dinota A., Bilancia D., Romano R., Manzione L. Biweekly administration of gemcitabine and vinorelbine as first line therapy in elderly advanced breast cancer. Breast Cancer Res Treat 2005, 89:1-3.
19. Rousseau F., Retornaz F., Joly F., Esterni B., Abadie-Lacourtoisie S., Fargeot P., et al. Impact of an all-oral capecitabine and vinorelbine combination regimen on functional status of elderly patients with advanced solid tumours: a multicentre pilot study of the French geriatric oncology group (GERICO). Crit Rev Oncol Hematol 2010, 76:71-78.
20. Feher O, Vodvarka P, Jassem J, Morack G, Advani SH, Khoo KS et al. First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study. Ann Oncol; 205;16:899-908.
21. Green H., Stål O., Bachmeier K., Bäcklund L.M., Carlsson L., Hansen J., et al. Pegylated liposomal doxorubicin as first-line monotherapy in elderly women with locally advanced or metastatic breast cancer: novel treatment predictive factors identified. Cancer Lett 2011, 313:145-153.
22. Mlineritsch B., Schabel-Moser R., Andel J., Fridrik M., Moik M., Mayer P., et al. Multicenter phase II study of pegylated liposomal doxorubicin in combination with vinorelbine as first-line treatment in elderly patients with metastatic breast cancer. Onkologie 2009, 32:18-24.
23. Addeo R., Faiola V., Guarrasi R., Montella L., Vincenzi B., Capasso E., et al. Liposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer in elderly women> or =65years of age. Cancer Chemother Pharmacol 2008, 62:285-292.
24. Extermann M., Boler I., Reich R.R., Lyman G.H., Brown R.H., DeFelice J., et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer 2012, 118:3377-3386.
25. Sargent D.J., Goldberg R.M., Jacobson S.D., Macdonald J.S., Labianca R., Haller D.G., et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001, 341:1091-1097.
26. Bellmunt J., Négrier S., Escudier B., Awada A., Aapro M. The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce. Crit Rev Oncol Hematol 2009, 69:64-72.